Gulliver W, Alavi A, Wiseman MC, et al. - During this 1-year period, the efficacy of adalimumab was maintained, and an optimal gain was documented for patients with medium and high inflammatory nodule (AN) counts. The findings revealed a prompt treatment of hidradenitis suppurativa (HS) patients and the use of an international HS severity scoring system (IHS4) to monitor treatment.

• From 23 Canadian centrers, at week 24, 69% of the 138 patients achieved hidradenitis suppurativa clinical response (HiSCR), which elevated to 82% and 75% at week 52 in patients with medium and high AN counts, respectively.

• The results indicated that gender (4 times the odds for females) and age at HS onset (5% decrease with each additional year) had an effect on achieving HiSCR.

• An important decrease in the number of lesions in responders after treatment with adalimumab, with most gains observed in inflammatory nodules, more frequently in the lower body area of patients in the high AN count group.

• With a larger decrease in patients of the high AN count group, the IHS4 scores of responders were substantially lowered.

• There was no new safety signal detected.